Table 1. Comparison of clinicopathologic factors between patients who underwent curative-intent resection and curative-intent transplatation.
| Variable | Resection (n=191, 82%) | Transplant (n=41, 18%) | p-value |
|---|---|---|---|
| Age (yrs), median (IQR) | 67 (57 – 73) | 54 (43 – 62) | <0.001 |
|
| |||
| Male, n (%) | 112 (59) | 29 (71) | 0.15 |
|
| |||
| BMI (kg/m2), median (IQR) | 25 (22 – 29) | 25 (22 – 28) | 0.52 |
|
| |||
| Race, n (%) | 0.41 | ||
| White | 148 (79) | 36 (88) | |
| African-American | 14 (7) | 2 (5) | |
| Other | 25 (14) | 3 (7) | |
|
| |||
| ASA Class, n (%) | <0.001 | ||
| 1 / 2 | 49 (31) | 2 (5) | |
| 3 / 4 | 109 (69) | 37 (95) | |
|
| |||
| Preoperative Labs, median (IQR) | |||
| Bilirubin (mg/dL) | 1.7 (0.9 – 3.6) | 0.8 (0.5 – 2.3) | 0.001 |
| Albumin (g/dL) | 3.4 (2.8 – 3.8) | 3.6 (2.9 – 3.8) | 0.32 |
| Creatinine (mg/dL) | 0.8 (0.7 – 1.0) | 0.8 (0.7 – 1.0) | 0.97 |
| INR | 1.0 (1.0 – 1.1) | 1.1 (1.0 – 1.2) | 0.004 |
|
| |||
| Primary Sclerosing Cholangitis, n (%) | 3 (2) | 25 (61) | <0.001 |
|
| |||
| Type of Resection, n (%) | |||
| Hemi-Hepatectomy + CBD Resection | 90 (47) | ||
| Extended Hepatectomy + CBD Resection | 58 (30) | — | — |
| Trisectionectomy + CBD Resection | 43 (22) | ||
|
| |||
| Major Complication, n (%) | 82 (45) | 14 (34) | 0.30 |
| Postoperative Liver Failure | 12 (7) | 4 (10) | 0.50 |
| 30-day Mortality | 15 (8) | 2 (5) | 0.74 |
| 90-day Mortality | 22 (12) | 2 (5) | 0.27 |
|
| |||
| Length of Stay (days), median (IQR) | 11 (7 – 18) | 8 (6 – 14) | 0.03 |
|
| |||
| Pathologic complete response, n (%) | — | 12 (29) | — |
|
| |||
| Final margin status, n (%) | 0.01 | ||
| R0 | 134 (70) | 36 (90) | |
| R1 | 57 (30) | 4 (10) | |
|
| |||
| Tumor size, median (IQR) | 3.0 (2.0 – 4.0) | 2.5 (1.1 – 5.0) | 0.51 |
|
| |||
| AJCC T-Stage, n (%) | 0.002 | ||
| Tis/T1 | 15 (10) | 8 (29) | |
| T2 | 100 (68) | 12 (44) | |
| T3 | 28 (19) | 5 (19) | |
| T4 | 4 (3) | 2 (7) | |
|
| |||
| Blumgart T-Stage, n (%) | 0.12 | ||
| T1 | 81 (46) | 15 (68) | |
| T2 | 42 (34) | 2 (9) | |
| T3 | 53 (30) | 5 (23) | |
|
| |||
| Bismuth Classification, n (%) | <0.001 | ||
| Type I | 8 (5) | 0 (0) | |
| Type II | 23 (13) | 16 (70) | |
| Type III | 108 (61) | 2 (9) | |
| Type IV | 37 (21) | 5 (23) | |
|
| |||
| Grade, n (%) | 0.14 | ||
| Low | 36 (20) | 5 (21) | |
| Intermediate | 102 (58) | 9 (38) | |
| High | 38 (22) | 10 (42) | |
|
| |||
| Lymphovascular invasion, n (%) | 63 (41) | 7 (18) | 0.02 |
|
| |||
| Perineural invasion, n (%) | 127 (78) | 13 (33) | <0.001 |
|
| |||
| Lymph nodes retrieved, n (%) | 169 (91) | 33 (83) | 0.17 |
|
| |||
| # Lymph nodes retrieved, median (IQR) | 4 (2 – 7) | 3 (1 – 5) | 0.04 |
|
| |||
| Lymph node positive, n (%) | 66 (38) | 7 (19) | 0.04 |
|
| |||
| Neoadjuvant therapy, n (%) | |||
| Chemotherapy | 9 (5) | 39 (95) | <0.001 |
| Radiation | 6 (3) | 39 (95) | <0.001 |
|
| |||
| Adjuvant therapy, n (%) | |||
| Chemotherapy | 89 (52) | 1 (3) | <0.001 |
| Radiation | 58 (35) | 1 (3) | <0.001 |
|
| |||
| Recurrence, n (%) | 65 (37) | 10 (24) | 0.19 |
| Isolated locoregional | 18 (29) | 2 (20) | 0.72 |
| Distant (liver, peritoneum, lung, other) | 45 (71) | 8 (80) | 0.72 |
| Isolated locoregional and/or liver only | 39 (62) | 2 (20) | 0.02 |
BMI, mass body index; IQR, interquartile range; ASA, American Society of Anesthesiologists; INR, international normalized ratio; CBD, common bile duct; AJCC, American Joint Committee on Cancer